Displaying drugs 14776 - 14800 of 15155 in total
Ritanserin
Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.
Investigational
2,2-bis(4-hydroxy-3-tert-butylphenyl)propane
TBD has been used in trials studying the treatment of Adenocarcinoma.
Investigational
Viminol
Experimental
Cibenzoline
Experimental
Budipine
Experimental
Cloranolol
Experimental
Levomethadone
Experimental
Sequifenadine
Experimental
Picloxydine
Experimental
Xibornol
Experimental
Guanoclor
Experimental
Motexafin lutetium
Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational
Talviraline
Talviraline has been used in trials studying the treatment of HIV Infections.
Investigational
4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
Experimental
Dexetimide
A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn
Mephenoxalone
Experimental
A-98881
Experimental
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
CCT-018159
Experimental
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages …
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
Displaying drugs 14776 - 14800 of 15155 in total